A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 to measure its effect on the diagnostic capabilities of [111In]-FPI-1547
The research team will work closely with colleagues in the Phase I oncology group at Penn Medicine treating solid tumors. Most subjects will be getting treatment in the University of Pennsylvania Health System. Screening will be carried out by the Phase I and nuclear medicine groups and nuclear medicine study team as necessary.
Participants will complete the following research procedures:
• Blood tests, urine tests, physical examination, ECGs, a biopsy and scans of your cancer (if you have not recently had either)
• An injection of the imaging study drug [111In] -FPI-1547 followed by four imaging scans over the course of one week
• An injection of the treatment study drug [225Ac]-FPI-1434
• Follow-up visits (in person or over the phone) which include a review of medications, how you are feeling
Study Identifier: 842694
Contact the research team to learn more about this study.